1380331-28-1

Upstream product

• 885588-14-7 methyl 2-bromo-5-fluoro-pyridine-4-carboxylate 
• 4248-19-5 tert-butyl carbazate 
• 885588-12-5 2-bromo-5-fluoropyridine-4-carboxylic acid 

Downstream Products

• 1380330-05-1 4-(azetidine-1-carbonyl)-N-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide 
• 1380331-29-2 methyl 2-amino-5-fluoroisonicotinate 
• 1380331-31-6 1,2-diamino-5-fluoro-4-(methoxycarbonyl)pyridinium 2,4,6-trimethylbenzenesulfonate 
• 1380331-32-7 methyl 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylate 
• 1380331-33-8 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylic acid 
• 1380331-34-9 tert-butyl 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamate 
• 1380331-35-0 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-amine 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES

The present invention relates to pyrrolopyrimidine compounds according to Formula (I) and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. (Formula (I))

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The